| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | APOA4 |
| Uniprot No | P06727 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-396aa |
| 氨基酸序列 | MFLKAVVLTLALVAVAGARAEVSADQVATVMWDYFSQLSNNAKEAVEHLQ KSELTQQLNALFQDKLGEVNTYAGDLQKKLVPFATELHERLAKDSEKLKE EIGKELEELRARLLPHANEVSQKIGDNLRELQQRLEPYADQLRTQVNTQA EQLRRQLTPYAQRMERVLRENADSLQASLRPHADELKAKIDQNVEELKGR LTPYADEFKVKIDQTVEELRRSLAPYAQDTQEKLNHQLEGLTFQMKKNAE ELKARISASAEELRQRLAPLAEDVRGNLRGNTEGLQKSLAELGGHLDQQV EEFRRRVEPYGENFNKALVQQMEQLRQKLGPHAGDVEGHLSFLEKDLRDK VNSFFSTFKEKESQDKTLSLPELEQQQEQQQEQQQEQVQMLAPLES |
| 预测分子量 | 72 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于APOA4重组蛋白的3-4条参考文献的示例(注：内容为虚构，仅作格式参考)：
1. **文献名称**：*Expression and Purification of Recombinant Human APOA4 in Escherichia coli*
**作者**：Chen L, Wang Y, et al.
**摘要**：该研究描述了一种高效表达和纯化重组人APOA4蛋白的方法，利用大肠杆菌表达系统，并通过色谱技术获得高纯度蛋白，为后续功能研究奠定基础。
2. **文献名称**：*Recombinant APOA4 Attenuates Atherosclerosis via Modulating Cholesterol Efflux in Mice*
**作者**：Smith JR, Brown K, et al.
**摘要**：通过动物实验证明，重组APOA4蛋白能够增强巨噬细胞的胆固醇逆向转运能力，显著减少动脉粥样硬化斑块的形成，提示其潜在治疗价值。
3. **文献名称**：*Structural Characterization of Recombinant APOA4 and Its Role in Lipid Metabolism*
**作者**：Gupta S, Lee M, et al.
**摘要**：利用X射线晶体学解析了重组APOA4的三维结构，并发现其通过结合脂质颗粒调节甘油三酯代谢，揭示了其与代谢综合征的关联。
4. **文献名称**：*Anti-inflammatory Effects of Recombinant APOA4 in Cellular Models of Intestinal Inflammation*
**作者**：Rodriguez A, Patel T, et al.
**摘要**：体外实验表明，重组APOA4蛋白可抑制炎症因子释放，缓解肠道上皮细胞炎症反应，提示其在炎症性肠病中的潜在应用。
(注：上述文献为模拟示例，实际文献需通过数据库如PubMed/Google Scholar检索确认。)
**Background of APOA4 Recombinant Protein**
Apolipoprotein A-IV (APOA4) is a glycoprotein primarily synthesized in the small intestine and plays a significant role in lipid metabolism, particularly in cholesterol transport and high-density lipoprotein (HDL) assembly. It is involved in regulating dietary fat absorption, glucose homeostasis, and anti-inflammatory responses. APOA4 is also implicated in atherosclerosis protection, satiety signaling, and neuroprotection, making it a protein of interest in metabolic and cardiovascular research.
Recombinant APOA4 protein is produced using genetic engineering techniques, often expressed in systems like *E. coli* or mammalian cell lines to ensure proper folding and post-translational modifications. This engineered protein retains the functional properties of native APOA4. enabling researchers to study its structure, interactions with lipids, and mechanisms in disease models. Its recombinant form allows for high purity and scalability, critical for experimental consistency and therapeutic development.
Current research focuses on APOA4's role in metabolic syndromes, obesity, and neurodegenerative disorders. Studies suggest it modulates triglyceride-rich lipoprotein metabolism and enhances insulin secretion, highlighting its potential as a therapeutic target. Additionally, recombinant APOA4 is used to develop diagnostic assays, investigate genetic variants linked to dyslipidemia, and explore its anti-inflammatory effects in conditions like sepsis or colitis.
Challenges in APOA4 research include understanding tissue-specific functions and resolving structural complexities due to its dynamic lipid-binding behavior. Nonetheless, advances in recombinant protein technology continue to drive insights into APOA4’s multifunctional biology, offering promising avenues for translational applications in metabolic and cardiovascular diseases.
×
